苯那普利联合厄贝沙坦对早期糖尿病肾病的干预研究

被引：5

作者：

杨栎 ^{[1
]}

吕肖锋 ^{[1
]}

常快乐 ^{[2
]}

机构：

[1] 北京军区总医院

[2] 解放军第三医院心血管内科

来源：

中国循证心血管医学杂志 | 2013年 / 5卷 / 05期

关键词：

苯那普利; 厄贝沙坦; 糖尿病肾病; 高敏C反应蛋白; 脂联素;

D O I：

暂无

中图分类号：

R587.2 [糖尿病性昏迷及其他并发症];

学科分类号：

1002 ; 100201 ;

摘要：

目的研究苯那普利联合厄贝沙坦对早期糖尿病肾病（diabetic nephropathy,DN）患者肾功能、血浆脂联素（adiponectin,APN）和高敏C反应蛋白（high sensitivity-C response protein,hs-CRP）的影响。方法纳入2011年1月2012年6月北京军区总医院内分泌科早期DN患者84例,所有患者均伴有1级高血压。随机分为常规组（n=42）及联合组（n=42）,常规组予苯那普利（10～20）mg,联合组予苯那普利10mg联合厄贝沙坦（150～300）mg,疗程均为3个月。比较两组治疗前后患者内生肌酐清除率（creatinine clearance rate,Ccr）、24小时尿蛋白定量（24 h-UPE）及血浆APN和hs-CRP水平。结果两组治疗后Ccr及血浆APN水平均较治疗前明显升高,24 h-UPE和hs-CRP水平均较治疗前明显降低,差异有统计学意义（P<0.05）。与常规组相比,联合组治疗后24 h-UPE[（124±23.1）mg/Lvs.（167±38.1）mg/L]和hs-CRP[（12.8±1.1）mg/Lvs.（4.1±1.3）mg/L]水平更低,而Ccr[（95±11.1）mL/minvs.（83±9.4）mL/min]和血浆APN[（6.1±1.6）mg/Lvs.（4.9±1.5）mg/L]水平更高,组间比较差异有统计学意义（P<0.05）。结论苯那普利联合厄贝沙坦治疗可更好地保护早期DN患者的肾功能,这可能与其能够较好地保护血管内皮功能和降低炎症反应有关。

引用

页码：467 / 469

页数：3

共 15 条

[1]

Adiponectin, Resistin and Leptin Response to Dietary Intervention in Diabetic Nephropathy[J] . &nbspJournal of Renal Nutrition . 2010 (4)

[2]

ANTIOXIDANTS AND REDOX SIGNALING[C]. Dipak K.Das.The Second International Symposium on Natural Antioxidants: Molecular Mechanisms and Health Effects,1600

[3]

A relationship between CRP, adiponectin and Gensini scow in the patients with coronary artery disease. Dursun Dursunoglu,Hidayet Goksoy,Mehmed Ozturk. ANADOLU KARDIYOLOJI DERGISI-THE ANATOLIAN JOURNAL OF CARDIOLOGY . 2011

[4]

2012 update on diabetic kidney disease: the expanding spectrum, novel pathogenic insights and recent clinical trials. Fernández Fernández B,Elewa U,Sánchez-Ni?o M D,Rojas-Rivera J E,Martin-Cleary C,Egido J,Ortiz A. Minerva Medica . 2012

[5]

The New KDOQITM Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and CKD. Robert G Nelson,Katherine R Tuttle. Blood Purification . 2007

[6] Urinary adiponectin excretion is increased in patients with overt diabetic nephropathy [J].

Koshimura, J ;

Fujita, H ;

Narita, T ;

Shimotomai, T ;

Hosoba, M ;

Yoshioka, N ;

Kakei, M ;

Fujishima, H ;

Ito, S .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2004, 316 (01) :165-169

[7] MicroalbuminuriaA Biomarker of Renal Microvascular Disease [J].

Futrakul, Narisa ;

Sridama, Vitaya ;

Futrakul, Prasit .

RENAL FAILURE, 2009, 31 (02) :140-143

[8]

Cardioprotective effect of adiponectin is partially mediated by its AMPK-independent antinitrative action. Wang Yajing,Tao Ling,Yuan Yuexin,Lau Wayne Bond,Li Rong,Lopez Bernard L,Christopher Theodore A,Tian Rong,Ma Xin-Liang. American journal of physiology. Endocrinology and metabolism . 2009

[9]

Association of adiponectin with future cardiovascular events in patients after acute myocardial infarction. Huang Shao-Sung,Huang Po-Hsun,Chen Ying-Hwa,Chiang Kuang-Hsing,Chen Jaw-Wen,Lin Shing-Jong. Journal of atherosclerosis and thrombosis . 2010

[10]

Combination therapy with renin-angiotensin system inhibitors and the calcium channel blocker azelnidipine decreases plasma inflammatory markers and urinary oxidative stress markers in patients with diabetic nephropathy. Ogawa Susumu,Mori Takefumi,Nako Kazuhiro,Ito Sadayoshi. Hypertension research : official journal of the Japanese Society of Hypertension . 2008

← 1 2 →